German medical cannabis company Demecan is expanding its cultivation operations at its Ebersbach site in Saxony, further strengthening domestic production capacity in a market that remains heavily dependent on imports.
The company has doubled its cultivation area at the facility, bringing annual in house production to more than 4 tons of medical cannabis. Alongside domestic cultivation, Demecan can now process an additional 6 to 8 tons of imported flower, resulting in a total annual production capacity of over 10 tons.
Germany currently imports close to 200 tons of medical cannabis per year, with projections bringing that number up to 600 tons per year, " it becomes clear how heavily the market still depends on imports," co-founder Constantin von der Groeben says. "With our cost efficient, high quality domestic production, we are confident that we will continue to gain market share."
© Demecan
The Ebersbach site is evolving into a fully integrated pharmaceutical operation, combining cultivation with an in house laboratory, quality control and dedicated research and development departments. "Under the leadership of our CEO, Dr. Adrian Fischer, we are strongly focused on innovation in cannabis-based medicine. With in-house cultivation, our own laboratory, and dedicated R&D departments, we are on a clear path to becoming a true phytopharmaceutical life science company," Constanin remarks.
The expansion has also drawn political attention at the regional level. Saxony's Prime Minister Michael Kretschmer recently visited the Ebersbach facility, alongside CDU Saxony General Secretary Tom Unger, to see the expanded production site firsthand.
In a statement shared by the Prime Minister of Saxony Michael Kretschmer, the regional government described the expansion as a strong signal for Saxony as a pharmaceutical location. "The expansion of the Demecan plant sends a strong signal for Saxony as a pharmaceutical hub. In just a few years, a modern production facility has been built in Ebersbach, which is now being systematically expanded. The company is now a key player in the medical cannabis sector in Germany and an important medium-sized employer in the region. The pharmaceutical industry, as a key sector in Saxony, stands for innovation, added value, and a secure supply of medicines."
Demecan echoed this sentiment. "We were honored to be visited by Saxony's Prime Minister Michael Kretschmer and are pleased to have strong support from the regional government. This further encourages us to continue on our growth path," Constantin concludes.
For more information:
Demecan
[email protected]
www.demecan.de
